First hypertension device therapy reaches Europe:
This article was originally published in Clinica
Executive Summary
The first ever device therapy for hypertension has been CE marked for sale in Europe. CVRx's Rheos baroreflex hypertension therapy system is an implantable device that electronically activates the patient's baroreflex - the body's own system for controlling blood pressure. The company is now enrolling patients in a US pivotal trial for the technology. Outcomes from the study will be used to support a premarket approval application to the US FDA. The Minneapolis, Minnesota company claims that hypertension affects some 65 million in the US alone. Of these, around 25% cannot control their high blood pressure despite the use of multiple therapies.